Journal
TRENDS IN IMMUNOLOGY
Volume 42, Issue 10, Pages 846-848Publisher
CELL PRESS
DOI: 10.1016/j.it.2021.08.011
Keywords
-
Categories
Funding
- Science Foundation Ireland [19/FFP/6625, 18/TIDA/6026]
- Irish Research Council [GOIPD/2020/16]
- Science Foundation Ireland (SFI) [18/TIDA/6026] Funding Source: Science Foundation Ireland (SFI)
Ask authors/readers for more resources
Targeting the glycolytic enzyme PFKL can effectively block neutrophil activation, which may have therapeutic benefits for infectious and inflammatory diseases.
Selectively targeting facets of neutrophil function could benefit infectious and inflammatory diseases. Amara et al. report on a compound which blocks human neutrophil activation by activating the glycolytic enzyme phosphofructokinase, liver type (PFKL). Altering glucose fate by modulating this key enzymatic step could dramatically alter the function and fate of phagocytes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
